WellDoc Expands Board of Directors

9-3-2013 9-51-24 PM

WellDoc announces the expansion of its board of directors to include David Levy, MD; Terry Lierman; Donald Almeida; and Michael Greenebaum. The new strategic leadership will help WellDoc as it moves to commercialize its flagship product BlueStar, the nation’s first FDA-cleared, reimbursable, mhealth app prescribed for type 2 diabetes.

Dr. Levy began his career as a primary care physician and epidemiologist in suburban New York City before moving on to help develop new business and care delivery models as a PwC consultant working in the healthcare sector.

Donald Almeida is also a PwC transplant, having recently retired as vice chairman. He oversaw Global Markets and Industries in Healthcare, Pharmaceutical, Life Sciences, and Government practices.

Michael Greenebaum is an interesting addition because he comes from the real estate industry, where he has worked the last 25 years. His connection with healthcare comes through several board member positions he holds, one for his families philanthropic foundation the Greenebaum Family Foundation, which focuses on improving the human condition through education and medicine. He also sits on the board of the University of Maryland School of Medicine, and the Stewart Greenebaum Cancer Center.

Terry Lierman began his career at the National Institutes of Health and went on to serve in various roles both public and private. He founded the Children’s Research Institute and the National Coalition for Cancer Research, and serves as the chairman of the Democratic Party in Maryland.

In addition to the expanded board, WellDoc has established a strategic advisory board that will also play a role in guiding the company through the launch and commercialization of BlueStar.

↑ Back to top

Founding Sponsors

Platinum Sponsors